Clinical Trials Browser

Phase 1 × Esophageal Neoplasms × MK 2206 × Clear all

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male